{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:23:56Z","timestamp":1792700636078,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ccm.2019.07.008","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T17:14:13Z","timestamp":1573578853000},"page":"839-848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Treatment of Latent Tuberculosis Infection\u2014An Update"],"prefix":"10.1016","volume":"40","author":[{"given":"Moises A.","family":"Huaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2019.07.008_bib1","series-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"World Health Organization","year":"2018"},{"issue":"10","key":"10.1016\/j.ccm.2019.07.008_bib2","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a Re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.ccm.2019.07.008_bib3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1183\/09031936.00214014","article-title":"Towards tuberculosis elimination: an action framework for low-incidence countries","volume":"45","author":"Lonnroth","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2019.07.008_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-publhealth-031912-114431","article-title":"Prospects for tuberculosis elimination","volume":"34","author":"Dye","year":"2013","journal-title":"Annu Rev Public Health"},{"issue":"4","key":"10.1016\/j.ccm.2019.07.008_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1164\/rccm.201508-1683OC","article-title":"The prevalence of latent tuberculosis infection in the United States","volume":"194","author":"Mancuso","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2019.07.008_bib6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1164\/rccm.200701-057OC","article-title":"Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000","volume":"177","author":"Bennett","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ccm.2019.07.008_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.15585\/mmwr.mm6611a3","article-title":"Tuberculosis among foreign-born persons diagnosed\u00a0>\/=10 years after arrival in the United States, 2010-2015","volume":"66","author":"Tsang","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.ccm.2019.07.008_bib8","doi-asserted-by":"crossref","first-page":"e0153728","DOI":"10.1371\/journal.pone.0153728","article-title":"Recent transmission of tuberculosis - United States, 2011-2014","volume":"11","author":"Yuen","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ccm.2019.07.008_bib9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/aje\/kwt246","article-title":"Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup","volume":"179","author":"Shea","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.ccm.2019.07.008_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.15585\/mmwr.mm6711a2","article-title":"Tuberculosis - United States, 2017","volume":"67","author":"Stewart","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.ccm.2019.07.008_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMp1707387","article-title":"Tuberculosis elimination in the United States - the need for renewed action","volume":"377","author":"Bayer","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"33","key":"10.1016\/j.ccm.2019.07.008_bib12","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0901720106","article-title":"Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics","volume":"106","author":"Abu-Raddad","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ccm.2019.07.008_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40506-017-0135-7","article-title":"Treatment of latent tuberculosis infection","volume":"9","author":"Tang","year":"2017","journal-title":"Curr Treat Options Infect Dis"},{"issue":"10010","key":"10.1016\/j.ccm.2019.07.008_bib14","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(15)00323-2","article-title":"Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection","volume":"386","author":"Rangaka","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ccm.2019.07.008_bib15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.ccm.2019.07.008_bib16","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ccm.2019.07.008_bib17","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2016.11046","article-title":"Screening for latent tuberculosis infection in adults: US preventive services task force recommendation statement","volume":"316","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ccm.2019.07.008_bib18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/cid\/ciw836","article-title":"Diabetes mellitus and latent tuberculosis infection: a systemic review and metaanalysis","volume":"64","author":"Lee","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.ccm.2019.07.008_bib19","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1371\/journal.pmed.0050152","article-title":"Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies","volume":"5","author":"Jeon","year":"2008","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.ccm.2019.07.008_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/QCO.0000000000000253","article-title":"Diagnosis and management of latent tuberculosis","volume":"29","author":"Turetz","year":"2016","journal-title":"Curr Opin Infect Dis"},{"issue":"22","key":"10.1016\/j.ccm.2019.07.008_bib21","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccm.2019.07.008_bib22","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"10.1016\/j.ccm.2019.07.008_bib23","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2019.07.008_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","article-title":"Preventive therapy for latent tuberculosis infection-the promise and the challenges","volume":"56","author":"Fox","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3201\/eid1205.050681","article-title":"Isoniazid preventive therapy and risk for resistant tuberculosis","volume":"12","author":"Balcells","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.ccm.2019.07.008_bib26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.5588\/ijtld.15.0908","article-title":"Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis","volume":"20","author":"den Boon","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.ccm.2019.07.008_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/AAC.2.1.29","article-title":"Effect of isoniazid on the in\u00a0vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis","volume":"2","author":"Takayama","year":"1972","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ccm.2019.07.008_bib28","first-page":"371","article-title":"Preventive therapy of tuberculous infection","volume":"110","year":"1974","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2019.07.008_bib29","first-page":"297","article-title":"Preventive treatment in tuberculosis: a statement by the Committee on therapy, American Thoracic Society","volume":"91","author":"Runyon","year":"1965","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"10.1016\/j.ccm.2019.07.008_bib30","first-page":"1","article-title":"Prevention of experimental tuberculosis with isoniazid","volume":"73","author":"Ferebee","year":"1956","journal-title":"Am Rev Tuberc"},{"issue":"4","key":"10.1016\/j.ccm.2019.07.008_bib31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ccm.2019.07.008_bib32","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union against Tuberculosis Committee on Prophylaxis","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"issue":"10","key":"10.1016\/j.ccm.2019.07.008_bib33","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ccm.2019.07.008_bib34","series-title":"Latent tuberculosis infection: a guide for primary health care providers","year":"2013"},{"issue":"9","key":"10.1016\/j.ccm.2019.07.008_bib35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Bliven-Sizemore","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.ccm.2019.07.008_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00002018-200225020-00005","article-title":"Clinically significant interactions with drugs used in the treatment of tuberculosis","volume":"25","author":"Yew","year":"2002","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.ccm.2019.07.008_bib37","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial rna polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5588\/ijtld.11.0504","article-title":"Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial","volume":"16","author":"Chan","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"10.1016\/j.ccm.2019.07.008_bib40","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib41","first-page":"300","article-title":"[Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]","volume":"25","author":"Geijo","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"12","key":"10.1016\/j.ccm.2019.07.008_bib42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A\u00a0trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration","volume":"337","author":"Whalen","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1157\/13102265","article-title":"Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients","volume":"25","author":"Rivero","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"1","key":"10.1016\/j.ccm.2019.07.008_bib44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A\u00a0double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong\u00a0Chest Service\/Tuberculosis Research Centre, Madras\/British Medical Research Council","volume":"145","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib45","first-page":"161","article-title":"Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group","volume":"115","author":"Martinez Alfaro","year":"2000","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib46","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin\u00a0plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis","volume":"40","author":"Ena","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.ccm.2019.07.008_bib47","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1128\/AAC.43.9.2126","article-title":"Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis","volume":"43","author":"Miyazaki","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"6 Pt 1","key":"10.1016\/j.ccm.2019.07.008_bib48","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1541","article-title":"Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice","volume":"148","author":"Ji","year":"1993","journal-title":"Am Rev Respir Dis"},{"issue":"23","key":"10.1016\/j.ccm.2019.07.008_bib49","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccm.2019.07.008_bib50","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ccm.2019.07.008_bib51","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"issue":"25","key":"10.1016\/j.ccm.2019.07.008_bib52","doi-asserted-by":"crossref","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent mycobacterium tuberculosis infection","volume":"67","author":"Borisov","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.ccm.2019.07.008_bib53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/14656560802694564","article-title":"Tuberculosis pharmacotherapy: strategies to optimize patient care","volume":"10","author":"Mitnick","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.ccm.2019.07.008_bib54","doi-asserted-by":"crossref","first-page":"e0207582","DOI":"10.1371\/journal.pone.0207582","article-title":"A\u00a0scoring strategy for progression risk and rates of treatment completion in subjects with latent tuberculosis","volume":"13","author":"Scolarici","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib55","first-page":"498","article-title":"Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results","volume":"12","author":"Menzies","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.ccm.2019.07.008_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/2049-632X.12060","article-title":"Co-infection with Mycobacterium tuberculosis and human immunodeficiency virus: an overview and motivation for systems approaches","volume":"69","author":"Deffur","year":"2013","journal-title":"Pathog Dis"},{"issue":"9","key":"10.1016\/j.ccm.2019.07.008_bib57","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","article-title":"A\u00a0prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection","volume":"320","author":"Selwyn","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ccm.2019.07.008_bib58","doi-asserted-by":"crossref","first-page":"e34156","DOI":"10.1371\/journal.pone.0034156","article-title":"Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community","volume":"7","author":"Gupta","year":"2012","journal-title":"PLoS One"},{"issue":"9944","key":"10.1016\/j.ccm.2019.07.008_bib59","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","article-title":"Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial","volume":"384","author":"Rangaka","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ccm.2019.07.008_bib60","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A\u00a0trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Danel","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccm.2019.07.008_bib61","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/QAD.0b013e328216f441","article-title":"The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil","volume":"21","author":"Golub","year":"2007","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib62","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/QAD.0b013e328327964f","article-title":"Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort","volume":"23","author":"Golub","year":"2009","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.ccm.2019.07.008_bib64","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","author":"Akolo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.ccm.2019.07.008_bib65","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.ccm.2019.07.008_bib66","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkt483","article-title":"Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers","volume":"69","author":"Weiner","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.ccm.2019.07.008_bib67","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ccm.2019.07.008_bib68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciy082","article-title":"Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine","volume":"67","author":"Brooks","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2019.07.008_bib69","unstructured":"Swindells S, Ramchandani R, Gupta A, et\u00a0al. One month of rifapentine\/isoniazid to prevent TB in people with HIV: Brief-TB\/A5279. 25th CROI. Boston, MA. 4\u20137 March 2018. Oral abstract 37LB."},{"issue":"9777","key":"10.1016\/j.ccm.2019.07.008_bib70","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","article-title":"6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial","volume":"377","author":"Samandari","year":"2011","journal-title":"Lancet"},{"issue":"Suppl 4","key":"10.1016\/j.ccm.2019.07.008_bib71","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/ajt.12100","article-title":"Mycobacterium tuberculosis infections in solid organ transplantation","volume":"13","author":"Subramanian","year":"2013","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.ccm.2019.07.008_bib72","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/TP.0000000000001329","article-title":"Twelve-week rifapentine plus isoniazid versus 9-month isoniazid for the treatment of latent tuberculosis in renal transplant candidates","volume":"101","author":"Simkins","year":"2017","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.ccm.2019.07.008_bib73","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s15010-017-1004-5","article-title":"Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates","volume":"45","author":"Knoll","year":"2017","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.ccm.2019.07.008_bib74","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/TP.0b013e3182a94a2f","article-title":"Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates","volume":"97","author":"de Castilla","year":"2014","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ccm.2019.07.008_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ccm.2019.07.008_bib76","unstructured":"Gupta A, Montepiedra G, Aaron L, et\u00a0al. Randomised trial of safety of isoniazid preventive therapy during or after pregnancy. 25th CROI. Boston, MA. 4\u20137 March 2018. Oral abstract 142LB."},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib77","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1513\/AnnalsATS.201704-326OC","article-title":"Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials","volume":"15","author":"Moro","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.ccm.2019.07.008_bib78","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1008049","article-title":"Tuberculosis in children","volume":"367","author":"Perez-Velez","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 4","key":"10.1016\/j.ccm.2019.07.008_bib79","first-page":"1175","article-title":"Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents","volume":"114","year":"2004","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.ccm.2019.07.008_bib80","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1714284","article-title":"Safety and side effects of rifampin versus isoniazid in children","volume":"379","author":"Diallo","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccm.2019.07.008_bib81","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/520983","article-title":"The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study","volume":"45","author":"Spyridis","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ccm.2019.07.008_bib82","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/adc.2010.182600","article-title":"Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children","volume":"95","author":"Bright-Thomas","year":"2010","journal-title":"Arch Dis Child"},{"issue":"9760","key":"10.1016\/j.ccm.2019.07.008_bib83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(10)61972-1","article-title":"Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study","volume":"377","author":"Becerra","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ccm.2019.07.008_bib84","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.13.0028","article-title":"Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012","volume":"18","author":"Bamrah","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"10.1016\/j.ccm.2019.07.008_bib85","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/cix208","article-title":"Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis","volume":"64","author":"Marks","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2019.07.008_bib86","series-title":"Drug-resistant tuberculosis: a survival guide for clinicians","year":"2016"},{"key":"10.1016\/j.ccm.2019.07.008_bib87","series-title":"Canadian tuberculosis standards","year":"2013"},{"issue":"7","key":"10.1016\/j.ccm.2019.07.008_bib88","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciy230","article-title":"Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings","volume":"67","author":"Johnson","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ccm.2019.07.008_bib89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5588\/ijtld.17.0486","article-title":"Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges","volume":"22","author":"Swindells","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.ccm.2019.07.008_bib90","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.ccm.2019.07.008_bib91","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2019.07.008_bib92","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fmed.2017.00171","article-title":"Host-directed therapeutic strategies for tuberculosis","volume":"4","author":"Kolloli","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.ccm.2019.07.008_bib93","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect Dis"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523119300619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523119300619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:58:22Z","timestamp":1759453102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523119300619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0272523119300619"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2019.07.008","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Latent Tuberculosis Infection\u2014An Update","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2019.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}